Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 451-457 , October 2010

Male breast cancer

Received 23 December 2009 ,Revised 27 January 2010 ,Accepted 3 February 2010.

References 

  1. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367(18):595–604
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225
  3. Weiss JR, Moysich KB, Swede H. Epidemiology of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(1):20–26
  4. Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51–57
  5. Brinton LA, Richesson DA, Gierach GL, et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008;100:1477
  6. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53:538–549
  7. Thomas DB, Jimenez LM, McTiernan A, et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135:734–748
  8. Brenner B, Fried G, Levitzki P, et al. Male breast carcinoma in Israel: higher incident but possibly prognosis in Ashkenazi Jews. Cancer. 2002;94(8):2128–2133
  9. Olsson H, Alm P, Aspegren K, et al. Increased plasma prolactin levels in a group of men with breast cancer – a preliminary study. Anticancer Res. 1990;10:59
  10. McClure JA, Higgins CC. Bilateral carcinoma of male breast after estrogen therapy. JAMA. 1951;146:7–9
  11. Symmers WSC. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Brit Med J. 1968;2:83–85
  12. Ballerini P, Recchione C, Cavalleri A, et al. Hormones in male breast cancer. Tumori. 1990;76:26
  13. Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter’s syndrome. J Med Genet. 1971;8:460–461
  14. Hultborn R, Hanson C, Kopf I, et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17:4293–4297
  15. Rosenblatt KA, Thomas DB, McTiernan A, et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991;83:849–854
  16. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678
  17. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92:1126–1135
  18. Ottini L, Masala G, D’Amico C, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63:342
  19. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22:735
  20. Machado PM, Brandao RD, Cavaco BM, et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol. 2007;25:2027
  21. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:1811
  22. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res. 2002;4:R2
  23. Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60:313–319
  24. Mavraki E, Gray IC, Bishop DT, Spurr NK. Germline BRCA2 mutations in men with breast cancer. Brit J Cancer. 1997;76:1428
  25. Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58:1367
  26. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13:123–125
  27. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079–1084
  28. Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res. 1999;59:995–998
  29. Diez O, Cortes J, Domenech M, et al. BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol. 2000;11:81–84
  30. Sverdlov RS, Barshack I, Bar Sade RB, et al. Genetic analyses of male breast cancer in Israel. Genet Test. 2000;4:313–317
  31. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–1490
  32. Kwiatkowska E, Teresiak M, Filas V, et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res. 2003;9:4452–4459
  33. National Comprehensive Cancer Network (NCCN). Guidelines available online at www.nccn.org.
  34. Fackenthal JD, March DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38:159
  35. Boyd J, Rhei E, Federici MG, et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 1999;53:87
  36. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10:471–479
  37. Sorensen HT, Friis S, Olsen JH, et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol. 1998;93:231–233
  38. Weiderpass E, Ye W, Adami HO, et al. Breast cancer risk in male alcoholics in Sweden. Cancer Cause Control. 2001;12:661–664
  39. Hsing AW, McLaughlin JK, Cocco P, et al. Risk factors for male breast cancer (United States). Cancer Cause Control. 1998;9:269–275
  40. Evans GF, Anthony T, Turnage RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg. 2001;181:96–100
  41. Appelbaum AH, Evans GF, Levy KR, et al. Mammographic appearances of male breast disease. Radiographics. 1999;19:559
  42. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  43. Visfeldt J, Scheike O. Male breast cancer. 1: histologic typing and grading of 187 Danish cases. Cancer. 1973;32:985–990
  44. Stalsberg H, Thomas DB, Rosenblatt KA, et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Cause Control. 1993;4:143–151
  45. Wick MR, Sayadi H, Ritter JH, et al. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999;111:59–69
  46. Willsher PC, Leach IH, Ellis IO, et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997;17:2335–2338
  47. Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer. 1998;83:1947–1955
  48. Pich A, Margaria E, Chiusa L, et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Brit J Cancer. 1999;79:959–964
  49. Kidwai N, Gong Y, Sun X, et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res. 2004;6:R18–R23
  50. Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182:389–392
  51. Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003;127:36–41
  52. Rudlowski C, Friedrichs N, Farldl A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat. 2004;84:215
  53. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874
  54. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423
  55. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–10398
  56. Ge Y, Sneige N, Eltorky MA, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Brit Cancer Res. 2009;11:R28
  57. Ouriel K, Lotze MT, Hinshaw JR. Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet. 1984;159:373–376
  58. Gough DB, Donohue JH, Evans MM, et al. A 50-year experience of male breast cancer: is outcome changing?. Surg Oncol. 1993;2:325–333
  59. Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A:1960–1964
  60. Maddox WA, Carpenter JT, Laws HL, et al. A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg. 1983;198:207–212
  61. Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol. 1998;24:548–552
  62. Albo D, Ames FC, Hunt KK, et al. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat. 2003;77:9–14
  63. Cimmino VM, Degnim AC, Sabel MS, et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol. 2004;86:74–77
  64. Goyal A, Horgan K, Kissin M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol. 2004;30:480–483
  65. Port ER, Fey JV, Cody HS, et al. Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer. 2001;91:319–323
  66. De Cicco C, Baio SM, Veronesi P, et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun. 2004;25:139–143
  67. Gentilini O, Chagas E, Zurida S, et al. Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist. 2007;12:512
  68. Boughey JC, Bedroslan I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006;203:475
  69. Lyman GH, Giuliano AE, Smerfield MR, et al. American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703
  70. Donegan WL, Redlich PN, Lang PJ, et al. Carcinoma of the breast in males: a multiinstitutional survey. Cancer. 1998;83:498–509
  71. Spence RA, MacKenzie G, Anderson JR, et al. Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases. Cancer. 1985;55:648–652
  72. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol. 1984;2:903–909
  73. Schuchart U, Seegenschmiedt MH, Kirschner MJ, et al. Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience. Am J Clin Oncol. 1996;19:330
  74. Scott-Conner CE, Hochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999;126:775
  75. Goss PE, Reid C, Pintilie M, et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85:629–639
  76. Ribeiro G, Swindell R, Harris M, et al. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast. 1996;5:141–146
  77. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Brit J Cancer. 1992;65:252–254
  78. Giordano SH, Perkins G, Garcia SM, et al. Male breast cancer: the M.D. Anderson experience with adjuvant therapy. Breast Cancer Res Treat. 2003;82:S42
  79. Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74:74–77
  80. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987;2:171–5.
  81. Giordano SH, Valero V, Buzdar AU, et al. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002;25:235–237
  82. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol. 2005;90:26–30
  83. Mauras N, O’Brien KO, Klein KO, et al. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85:2370–2377
  84. Bagley CS, Wesley MN, Young RC, et al. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987;10:55–60
  85. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989;64:1583–1585
  86. Izquierdo MA, Alonso C, De Andres L, et al. Male breast cancer. Report of a series of 50 cases. Acta Oncol. 1994;33:767–771
  87. Giordano SH, Perkins GH, Brogio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104:2359
  88. Farrow J, Adair F. Effect of orchiectomy on skeletal metastases from cancer of the male breast. Science. 1942;95:654
  89. Jaiyesimi IA, Buzdar AU, Sahin AA, et al. Carcinoma of the male breast. Ann Intern Med. 1992;117:771–777
  90. Lopez M, Di Lauro L, Lazzaro B, et al. Hormonal treatment of disseminated male breast cancer. Oncology. 1985;42:345–349
  91. Labrie F, Dupont A, Belanger A, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med. 1990;13:275–278
  92. Lopez M, Natali M, Di Lauro L, et al. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer. 1993;72:502–505
  93. Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH–RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer. 1988;62:474–478
  94. Italiano A, Largillier R, Marcy PY, et al. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne. 2004;25:323–324[French]
  95. Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced males breast cancer. Breast Cancer Res Treat. 2007;101:123
  96. Yap HY, Tashima CK, Blurmenschein GR, et al. Chemotherapy for advanced male breast cancer. JAMA. 1980;243:1739
  97. Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer. 1993;71:154–161
  98. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res Treat. 2004;83:77
  99. Herman K, Lowaziewicz W, Stotnicki P, et al. Male breast cancer. Does the prognosis differ compared to female?. Neoplasma. 2000;47:191
  100. Borgen PI, Senle RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997;173:185
  101. Willsher PC, Leach IH, Ellis IO, et al. A comparison outcome of male breast cancer with females breast cancer. Am J Surg. 1997;173:185
  102. Crew KD, Neugult AI, Wang X, et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol. 2007;25:1089
  103. Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison of prognostic markers detected by immunochemistry in male and female breast carcinomas. Eur J Cancer. 1996;32A:1686
  104. Pich A, Margaria E, Chilusa L. Oncogenes and male breast carcinoma: c-erbB2 and p53 coexpression predicts poor survival. J Clin Oncol. 2000;18:2948
  105. Wang-Rodríguez J, Cross K, Gallagher S, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu and p53 with treatment and survival. A study of 65 cases. Mod Pathol. 2002;15:853
  106. Shpitz B, Bomsein Y, Sternberg A, et al. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol. 2000;75:5287
  107. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116
  108. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, et al. Clinical relevance or biologic factors in male breast cancer. Breast Cancer Res Treat. 2001;68:249
  109. Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 2002;94:1330–1332
  110. Dong C, Hemminki K. Second primary breast cancer in men. Breast Cancer Res Treat. 2001;66:171–172

PII: S0305-7372(10)00022-8

doi: 10.1016/j.ctrv.2010.02.002

Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 451-457 , October 2010

Article Tools